Therma Bright Inc.

Description

Therma Bright Inc is a healthcare technology company that provides medical devices and instruments, primarily dermatological products. The junior medical tech company offers skincare solutions, pain and health management solutions.

The firm’s stocks are listed on the TSX Venture Exchange (TSXV) under ‘THRM’ ticker symbol.

Therma Bright uses a proprietary thermal therapy that provides medicinal solutions to skin irritation and cold sores. Its diversified product offering includes:

Venowave

It is a massage device to prevent blood clotting due to Venowave Deep Vein Thrombosis. The product enables the patients to perform the exercise without pain by providing flexibility in body movements.

Benepod

It is a hot and cold stimulus solution for chronic pain resulting from aches and muscles soreness.
InterceptCS

InterceptCS is a cold sore prevention solution.

TherOZap

TherOZap is a thermal therapy-based device that reduces inflammation and itchiness due to insect bites and stings, including mosquito, bee, spider, mite, and jellyfish bites.

The medical tech company owns trademarks, patents and intellectual property, including research and development for all the products.

In addition, the Toronto-based healthcare company claims to have developed a COVID-19 diagnostic solution, AcuVid™, which is a rapid antigen saliva test.

AcuVid™ is a 15-minutes test that detects IgM and IgG antibodies against the original Wuhan novel coronavirus, SARS-CoV-2, and its different variants, the company claims.

In June, 2021, the medical technology company announced that its AcuVid™ had passed the Brazilian Clinical Study in Minas Gerais, Brazil. On June 24, 2021, the company announced to conduct AcuVid test on the delta variant of COVID-19 reportedly.

Therma Bright claims to have been recognized as a Class II medical device manufacturer in the United States Food and Drug Administration (FDA) for its skincare and pain management solutions.

The healthcare company is also focused on developing treatment for joint pain. Furthermore, the firm is also aiming at commercializing its product through online marketplaces and media networks and through its network of retailers in key markets across North America.

On May 21, 2021, the TSX-listed medical tech firm reportedly partnered with K-One MediTech, a certified medical device manufacturer, for developing, producing and commercializing its AcuVid™ COVID-19 Rapid Antigen Saliva Test in Asia.